Rhythm Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Rhythm Pharmaceuticals, Inc. specializes in the development of molecule therapies targeting metabolic pathways for the treatment of obesity, diabetes, and gastrointestinal functional disorders.
Rhythm Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Rhythm Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Rhythm Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Rhythm Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Rhythm Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Rhythm Pharmaceuticals assets
Rhythm Pharmaceuticals cash flows

Rhythm Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
RYTM:USRhythm Pharmaceuticals, Inc.Common share-US76243J1051$38.01
Rhythm Pharmaceuticals news
03.05.2022
Rhythm Pharmaceuticals' GAAP loss for 3 months of 2022 was $52.764 million, compared to a profit of $43.75 million in the previous year. Revenue increased 42.8 times to $1.498 million from $0.035 million a year earlier.
01.03.2022
Rhythm Pharmaceuticals' GAAP loss for 2021 was $69.612 million, down 48% from $133.996 million the previous year. Revenue was $3.154 million. The company had no revenue a year earlier.
06.12.2021
Rhythm Pharmaceuticals has granted RareStone exclusive rights to develop and commercialize setmelanotide in China. The drug is used to treat severe obesity and hyperphagia. Rhythm will receive $12 million in cash and stock in RareStone, and will be entitled to receive up to $63.5 million, if certain development milestones are reached, and royalties on sales.
02.11.2021
Rhythm Pharmaceuticals' GAAP loss for 9M 2021 was $26.746 million, down 3.7 times from $99.099 million in the previous year. Revenues were $1,337 million. A year earlier the company had not received revenues.
General information
Company nameRhythm Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address222 BERKELEY STREET 12TH FLOOR BOSTON MA 02116 857-264-4280
Mailing address222 BERKELEY STREET 12TH FLOOR BOSTON MA 02116
Websitewww.rhythmtx.com
Information disclosurewww.sec.gov